Cargando…
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression <1% and absence of HER2 amplification/overexpression. HER2-negative breast cancer with low ER/PR expression (1–10%) has a gene expression profile si...
Autores principales: | Yoder, Rachel, Kimler, Bruce F., Staley, Joshua M., Schwensen, Kelsey, Wang, Yen Y., Finke, Karissa, O’Dea, Anne, Nye, Lauren, Elia, Manana, Crane, Gregory, McKittrick, Richard, Pluenneke, Robert, Madhusudhana, Sheshadri, Beck, Larry, Shrestha, Anuj, Corum, Larry, Marsico, Mark, Stecklein, Shane R., Godwin, Andrew K., Khan, Qamar J., Sharma, Priyanka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273627/ https://www.ncbi.nlm.nih.gov/pubmed/35817765 http://dx.doi.org/10.1038/s41523-022-00448-4 |
Ejemplares similares
-
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
por: Stecklein, Shane R., et al.
Publicado: (2023) -
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer
por: Sharma, Priyanka, et al.
Publicado: (2014) -
Minerals Form a Continuum Phase in Mature Cancellous Bone
por: Chen, Po-Yu, et al.
Publicado: (2011) -
Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022) -
Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary Stents
por: McKittrick, C. M., et al.
Publicado: (2015)